Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage …
12 hours ago · (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer …
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
7 hours ago · On Friday, Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in …
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free ...
1 day ago · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational …
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free ...
12 hours ago · Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer Business Wire Fri, …
Pfizer's bladder cancer therapy meets main goal in late-stage study
12 hours ago · Jan 10 (Reuters) - Pfizer's (PFE.N), opens new tab experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain …
Pfizer’s Sasanlimab in Combination with BCG Improves Event
8 hours ago · This release contains forward-looking information about Pfizer Oncology, sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with Bacillus …
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
7 hours ago · Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer. ... free reports and …
Pfizer's Sasanlimab Breaks New Ground In Non-Muscle Invasive Bladder Cancer
11 hours ago · Pfizer Inc. (), on Friday, announced that its pivotal Phase 3 trial of investigational anti-PD-1 monoclonal antibody, Sasanlimab, in patients with BCG-naïve, high-risk non-muscle …
Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study
12 hours ago · Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in bladder cancer, positioning the Big Pharma …
Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder …
1 day ago · Pfizer said a late-stage study of its sasanlimab drug candidate met its key goal in certain patients with bladder cancer. ... Dow Jones Newswires is a market-moving financial …
- Some results have been removed